摘要 |
Disclosed are bis(thio-hydrazide amide) disalts, which are represented by Structural Formula (I): Y is a covalent bond or a substituted or unsubstituted straight chained hydrocarbyl group. R<SUB>1</SUB>-R<SUB>4 </SUB>are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R<SUB>1 </SUB>and R<SUB>3 </SUB>taken together with the carbon and nitrogen atoms to which they are bonded, and/or R<SUB>2 </SUB>and R<SUB>4 </SUB>taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. Z is -O or -S. M<SUP>+</SUP> is a pharmaceutically acceptable monovalent cation and M<SUP>2+ </SUP>is a pharmaceutically acceptable divalent cation. Also, disclosed are pharmaceutical compositions comprising a bis(thio-hydrazide amide) disalt described above. Further disclosed are methods of treating a subject with cancer. The methods comprise the step of administering an effective amount of a bis(thio-hydrazide amide) disalt described above.
|